Bronchopulmonary dysplasia

Lancet

Volumn 367, Issue 9520, 2006, Pages 1421-1431

  Kinsella, John P ^a   Greenough, Anne ^b   Abman, Steven H ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; CORTICOSTEROID; FLUTICASONE PROPIONATE; HYDROCORTISONE; OXYGEN; PROTIRELIN; STEROID; SURFACTANT;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; FOLLOW UP; GROWTH; HEALTH CARE PLANNING; HOSPITAL ADMISSION; HUMAN; LUNG CIRCULATION; LUNG DYSPLASIA; LUNG FUNCTION; LUNG INJURY; LUNG VENTILATION; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PATHOGENESIS; PREMATURITY; PRIORITY JOURNAL; PROPHYLAXIS; RESPIRATORY DISTRESS; RESPIRATORY TRACT DISEASE; REVIEW; SAFETY; SURVIVAL;

EID: 33646137788     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)68615-7     Document Type: Review

References (131)

1. Northway Jr. W., Rosan R., and Porter D. Pulmonary disease following respiratory therapy of hyaline membrane disease. N Engl J Med 276 (1967) 357-368
2. Bland R., and Coalson J. Chronic lung disease in early infancy (2000), Marcel Dekker, New York
3. Jobe A., and Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 163 (2001) 1723-1729
4. Bancalari E., Abdenour G., Feller R., and Gannon J. Bronchopulmonary dysplasia: clinical presentation. J Pediatr 95 (1979) 819-823
5. Jobe A. The new bronchopulmonary dysplasia: an arrest of lung development. Pediatr Res 46 (1999) 641-643
6. Charafeddine L., D'Angio C., and Phelps D. Aytypical chronic lung disease patterns in neonates. Pediatrics 103 (1999) 759-760
7. Rojas M., Gonzalez A., Bancalari E., et al. Changing trends in the epidemiology and pathogenesis of chronic lung disease. J Pediatr 126 (1995) 605-610
8. Smith V., Zupancic J., McCormick M., et al. Trends in severe BPD rates between 1994 and 2002. J Pediatr 146 (2005) 469-473
9. Hussain A., Siddiqui N., and Stocker J. Pathology of arrested acinar development in postsurfactant bronchopulmonary dysplasia. Hum Pathol 29 (1998) 710-717
10. Bancalari E., and Gonzalez A. Clinical course and lung function abnormalities during development of chronic lung disease. In: Bland R., and Coalson J. (Eds). Chronic lung disease in early infancy (2000), Marcel Dekker, New York
11. Coalson J. Pathology of chronic lung disease of early infancy. In: Bland R., and Coalson J. (Eds). Chronic lung disease of early infancy (2000), Marcel Dekker, New York 85-124
12. Greenough A., Kavvadia V., Johnson A., Calvert S., Peacock J., and Karani J. A simple chest radiograph score to predict chronic lung disease in prematurely born infants. Br J Radiol 72 (1999) 530-533
13. Thomas M., Greenough A., Johnson A., et al. Frequent wheeze at follow up of very preterm infants-which factors are predictive?. Arch Dis Child Fetal Neonatal Ed 88 (2003) 329-332
14. Ellsbury D., Acarregui M., McGuiness G., and Klein J. Variability in the use of supplemental oxygen for bronchopulmonary dysplasia. J Pediatr 149 (2002) 247-249
15. Walsh M., Yao Q., Gettner P., et al. Impact of a physiologic definition on BPD rates. Pediatrics 114 (2004) 1305-1311
16. Shepard F., Gray J., and Stahlman M. Occurrence of pulmonary fibrosis in children who had idiopathic RDS. J Pediatr 65 (1964) 1078
17. Avery M., Tooley W., Keller J., et al. Is chronic lung disease in low birth weight infants preventable? A survey of eight centers. Pediatrics 79 (1987) 26-30
18. Hitti J., Krohn M., Patton D., et al. Amniotic fluid tumor necrosis factor-alpha and the risk of respiratory distress syndrome among preterm infants. Am J Obstet Gynecol 177 (1997) 50-56
19. Yoon B., Romero R., Jun J., et al. Amniotic fluid cytokines (interleukin-6, tumor necrosis factor-alpha, interleukin-1, and interleukin-8) and the risk for the development of bronchopulmonary dysplasia. Am J Obstet Gynecol 177 (1997) 825-830
20. Ghezzi F., Gomez R., Romero R., et al. Elevated interleukin-8 concentrations in amniotic fluid of mothers whose neonates subsequently develop bronchopulmonary dysplasia. Eur J Obstet Gynecol Reprod Biol 78 (1998) 5-10
21. Jobe A. Antenatal factors in the development of bronchopulmonary dysplasia. Semin Neonatol 8 (2003) 9-17
22. Jobe A., Newnham J., Willet K., et al. Effects of antenatal endotoxin and glucocorticoids on the lungs of preterm lambs. Am J Obstet Gynecol 18 (2000) 401-408
23. Polk D., Ikegami M., Jobe A., Sly P., Kohan R., and Newnham J. Preterm lung function after retreatment with antenatal betamethasone in preterm lambs. Am J Obstet Gynecol 176 (1997) 308-315
24. 2 -rich environment: the antioxidant enzymes in the developing rabbit lung. Pediatr Res 18 (1984) 240-244
25. Ogihara T., Okamoto R., Kim H., et al. New evidence for the involvement of oxygen radicals in triggering neonatal chronic lung disease. Pediatr Res 39 (1996) 117-119
26. White C., Avraham K., Shanley P., and Groner Y. Transgenic mice with expression of elevated levels of copper-zinc superoxide dismutase in the lungs are resistant to pulmonary oxygen toxicity. J Clin Invest 87 (1991) 2162-2168
27. Wispe J., Warner B., Clark J., et al. Human Mn-superoxide dismutase in pulmonary epithelial cells of transgenic mice confers protection from oxygen injury. J Biol Chem 267 (1992) 23937-23941
28. Ahmed M., Suliman H., Folz R., et al. Extracellular superoxide dismutase protects lung development in hyperoxia-exposed newborn mice. Am J Respir Crit Care Med 167 (2003) 400-405
29. Shah P., and Ohlsson A. Alpha-1 proteinase inhibitor (AIP1) for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 3 (2001) CD002775
30. Dreyfuss D., and Saumon G. Ventilator induced lung injury: lessons from experimental studies. Am J Respir Crit Care Med 157 (1998) 294-323
31. Hodson W. Ventilation strategies and bronchopulmonary dysplasia. In: Bland R., and Coalson J. (Eds). Chronic lung disease in early infancy (2000), Marcel Dekker, New York 173-208
32. Tremblay L., Valenza F., Ribeiro S., Li J., and Slutsky A. Injurious ventilatory strategies increase cytokines and c-fos m-RNA expression in an isolated rat lung model. J Clin Invest 99 (1997) 944-952
33. Carlton D., Cummings J., Scheerer R., Poulain F., and Bland R. Lung overexpansion increases pulmonary microvascular protein permeability in young lambs. J Appl Physiol 69 (1990) 577-583
34. Nilsson R., Grossman G., and Robertson B. Lung surfactant and the pathogenesis of neonatal bronchiolar lesions induced by artificial ventilation. Pediatr Res 12 (1978) 249-255
35. Pierce M., and Bancalari E. The role of inflammation in the pathogenesis of bronchopulmonary dysplasia. Pediatr Pulmonol 19 (1995) 371-378
36. Groneck P., and Speer C. Inflammatory mediators and bronchopulmonary dysplasia. Arch Dis Child Fetal Neonatal Ed 73 (1995) 1-3
37. Ozdemir A., Brown M., and Morgan W. Markers and mediators of inflammation in neonatal lung disease. Pediatr Pulmonol 23 (1997) 292-306
38. Jones C., Cayabyab R., Kwong K., et al. Undetectable interleukin (IL)-10 and persistent IL-8 expression early in hyaline membrane disease: a possible developmental basis for the predisposition to chronic lung inflammation in preterm newborns. Pediatr Res 39 (1996) 966-975
39. Ramsay P., O'Brian S., Hegemier S., and Welty S. Early clinical markers for the development of bronchopulmonary dysplasia: soluble E-Selectin and ICAM-1. Pediatrics 102 (1998) 927-932
40. Munshi U., Niu J., Siddiq M., and Parton L. Elevation of interleukin-8 and interleukin-6 precedes the influx of neutrophils in tracheal aspirates from preterm infants who develop bronchopulmonary dysplasia. Pediatr Pulmonol 24 (1997) 331-336
41. Wang E., Ohlson A., and Kellner J. Association of ureaplasma urealyticum colonisation with chronic lung disease of prematurity: results of meta-analysis. J Pediatr 127 (1995) 640-644
42. Howlett A., and Ohlsson A. Inositol for respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev 4 (2003) CD000366
43. Nickerson B., and Taussig L. Family history of asthma in infants with bronchopulmonary dysplasia. Pediatrics 65 (1980) 1140-1144
44. Clark D., Pincus L., Oliphant M., Hubbell C., Oates R., and Davey F. HLA-A2 and chronic lung disease. JAMA 248 (1982) 1868-1869
45. Kumar V., and Ryan R. Growth factors in the fetal and neonatal lung. Front Biosci 9 (2004) 464-480
46. Bhatt A., Pryhuber G., Huyck H., Watkins R., Metlay L., and Maniscalco W. Disrupted pulmonary vasculature and decreased VEGF, flt-1 and Tie 2 in human infants dying with bronchopulmonary dysplasia. Am J Respir Crit Care Med 164 (2000) 1971-1980
47. Jakkula M., Le Cras T., Gebb S., et al. Inhibition of angiogenesis decreases alveolarization in the developing rat lung. Am J Physiol Lung Cell Mol Physiol 279 (2000) 600-607
48. Bonikos D., Benson K., and Northway W. Oxygen toxicity in the newborn. The effect of chronic continuous 100 per cent oxygen exposure on the lung of newborn mice. Am J Pathol 85 (1976) 623-650
49. Crapo J., Peters-Golden M., Marsh-Salin J., et al. Pathologic changes in the lungs of oxygen-adapted rats. A morphometric analysis. Lab Invest 39 (1978) 640-653
50. Kraybill E., Runyan D., Bose C., et al. Risk factors for chronic lung disease in infants with birth weights of 751 to 1000 grams. J Pediatr 115 (1989) 115-120
51. Bjorklund L., Ingimarsson J., Curstedt T., et al. Manual ventilation with a few large breaths at birth compromises the therapeutic effect of subsequent surfactant replacement in immature lungs. Pediatr Res 42 (1997) 348-355
52. Gonzalez A., Sosenko I., Chandar J., et al. Influence of infection on patent ductus arteriosus and chronic lung disease in premature infants weighing 1000 g or less. J Pediatr 128 (1996) 470-478
53. Watterberg K., Demers L., Scott S., and Murphy S. Chorioamnionitis and early lung inflammation in infants in whom BPD develops. Pediatrics 97 (1996) 210-215
54. Moss T., Nitsos I., Kramer B., Ikegami M., Newnham J., and Jobe A. Intra-amniotic endotoxin induces lung maturation by direct effects on the developing respiratory tract in preterm sheep. Am J Obstet Gynecol 187 (2002) 1059-1061
55. Makri V., Hospes B., Stoll-Becker S., Borkhardt A., and Gortner L. Polymorphisms of surfactant protein B encoding gene: modifiers of the course of neonatal respiratory distress. Eur J Pediatr 161 (2002) 604-608
56. Hallman M., and Haataja K. Genetic influences and neonatal lung disease. Semin Neonatol 8 (2003) 19-27
57. Kotecha S., Wilson L., Wangoo A., et al. Increase in interleukin (IL)-1β and IL-6 in bronchoalveolar lavage fluid obtained from infants with chronic lung disease of prematurity. Pediatr Res 40 (1996) 250-256
58. Kojima T., Sasai M., and Kobayashi Y. Increased soluble ICAM-1 in tracheal aspirates of infants with bronchopulmonary dysplasia. Lancet 342 (1993) 1023-1024
59. Zimmerman J. Bronchoalveolar inflammatory pathophysiology of bronchopulmonary dysplasia. Clin Perinatol 22 (1995) 429-456
60. Merritt T., Cochrane C., Holcomb K., et al. Elastase and alpha-1 protease inhibitor activity in tracheal aspirates during RDS: the role of inflammation and pathogenesis of bronchopulmonary dysplasia. J Clin Invest 72 (1983) 656-666
61. Hallman M., Spragg R., Harrell J., et al. Evidence of lung surfactant abnormality in respiratory failure. J Clin Invest 70 (1982) 673-683
62. Murch S., Costeloe K., Klein N., et al. Mucosal tumour necrosis factor-α production and extensive disruption of sulfated glycosaminoglycans begin within hours of birth in neonatal respiratory distress syndrome. Pediatr Res 40 (1996) 484-489
63. Bacchi A., Viscardi R., Tacrak V., et al. Increased activity of interleukin-6 but not tumour necrosis factor-alpha in lung lavage of premature infants is associated with the development of bronchopulmonary dysplasia. Pediatr Res 36 (1994) 244-252
64. Mirro R., Armstead W., and Leffler C. Increased airway leukotriene levels in infants with severe bronchopulmonary dysplasia. Am J Dis Child 144 (1990) 160-161
65. Cook A., Yuksel B., Sampson A., et al. Cysteinyl leukotriene involvement in chronic lung disease in premature infants. Eur Respir J 9 (1996) 1907-1912
66. Bryan M., Hardie M., Reilly B., and Swyer P. Pulmonary function studies during the first year of life in infants recovering from respiratory distress syndrome. Pediatrics 52 (1973) 169-178
67. Goldman S., Gerhardt T., Sonni R., et al. Early prediction of chronic lung disease by pulmonary function testing. J Pediatr 102 (1983) 613-617
68. Wolfson M., Bhutani B., Shaffer T., and Bowen Jr. F. Mechanics and energetics of breathing helium in infants with bronchopulmnary dyspasia. J Pediatr 104 (1984) 752-757
69. Tepper R., Morgan W., Cota K., and Taussig L. Expiratory flow limitation in infants with bronchopulmonary dysplasia. J Pediatr 109 (1988) 1040-1046
70. Abman S. Pulmonary hypertension in chronic lung disease of infancy. Pathogenesis, pathophysiology and treatment. In: Bland R., and Coalson J. (Eds). Chronic Lung Disease of Infancy (2000), Marcel Dekker, New York 619-668
71. Parker T., and Abman S. The pulmonary circulation in bronchopulmonary dysplasia. Sem Neonatol 8 (2003) 51-61
72. Tomashefski J., Opperman H., and Vawter G. Bronchopulmonary dysplasia, a morphometric study with emphasis on the pulmonary vasculature. Pediatr Pathol 2 (1984) 469-487
73. Halliday H., Dumpit F., and Brady J. Effects of inspired oxygen on echocardiographic assessment of pulmonary vascular resistance and myocardial contractility in bronchopulmonary dysplasia. Pediatrics 65 (1980) 536-540
74. Abman S., Wolfe T., Accurso F., Koops B., and Wiggins J. Pulmonary vascular response to oxygen in infants with severe bronchopulmonary dysplasia. Pediatrics 75 (1985) 80-84
75. Mourani P., Ivy D., Gao D., and Abman S. Pulmonary vascular effects of inhaled nitric oxide and oxygen tension in bronchopulmonary dysplasia. Am J Respir Crit Care Med 170 (2004) 1006-1013
76. Apkon M., Nehgme R., and Lister G. Cardiovascular abnormalities in bronchopulmonary dysplasia. In: Bland R., and Coalson J. (Eds). Chronic lung disease of Infancy (2000), Marcel Dekker, New York 321-356
77. Walther F., Bendes F., and Leighton J. Persistent pulmonary hypertension in premature neonates with severe respiratory distress syndrome. Pediatrics 90 (1992) 899-904
78. Fouron J., LeGuennec J., Villemont D., et al. Value of echocardiography in assessing outcome of bronchopulmonary dysplasia. Pediatrics 65 (1980) 529-535
79. Goodman G., Perkin R., and Anas N. Pulmonary hypertension in infants with bronchopulmonary dysplasia. J Pediatr 112 (1988) 67-72
80. Anderson A., Warady B., Daily D., et al. Systemic hypertension in infants with severe bronchopulmonary dysplasia: associated clinical factors. Am J Perinatol 10 (1993) 190-193
81. Greenough A., Alexander J., Burgess S., et al. Health care utilisation of chronic lung disease infants related to hospitalisation for respiratory syncytial virus infection. Arch Dis Child 85 (2001) 463-468
82. Greenough A., Alexander J., Burgess S., et al. Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection. Arch Dis Child 89 (2004) 673-678
83. Baraldi E., Filippone M., Trevisanuto D., Zanardo V., and Zacchello F. Pulmonary function until two years of life in infants with bronchopulmonary dysplasia. Am J Respir Crit Care Med 155 (1997) 149-155
84. Gerhardt T., Hehre D., Feller R., Reifenberg L., and Bancalari E. Serial determinations of pulmonary function in infants with chronic lung disease. J Pediatr 110 (1987) 448-456
85. Filippone M., Sartor M., Zachello F., and Baraldi E. Flow limitation in infants with BPD and respiratory function at school age. Lancet 361 (2003) 753-754
86. Koumbourlis A., Motoyama E., Mutich R., Mallory G., Walczak S., and Fertal K. Longitudinal follow up of lung function from childhood to adolescence in prematurely born patients with neonatal chronic lung disease. Pediatr Pulmonol 21 (1996) 28-34
87. Northway W., Moss R., Carlisle K., et al. Late pulmonary sequelae of bronchopulmonary dysplasia. N Engl J Med 323 (1990) 1795-1799
88. Thomas M., Rafferty G., Limb E., et al. Pulmonary function at follow up of very preterm infants from the UK oscillation study. Am J Respir Crit Care Med 169 (2004) 868-872
89. Yuksel B., and Greenough A. Airways resistance and lung volume before and after bronchodilator therapy in symptomatic preterm infants. Respir Med 88 (1994) 281-286
90. Tschanz S., Damke B., and Burri P. Influence of postnatally administered glucocorticoids on rat lung growth. Biol Neonate 68 (1995) 229-245
91. Jacob S., Coates A., Lands L., et al. Long-term pulmonary sequalae of severe bronchopulmonary dysplasia. J Pediatr 133 (1998) 193-200
92. Short E., Klein N., Lewis B., et al. Cognitive and academic consequences of BPD and very low birth weight: 8 year old outcomes. Pediatrics 112 5 (2003) E359
93. Lewis B., Singer L., Fulton S., et al. Speech and language outcomes of children with bronchopulmonary dysplasia. J Commun Disord 35 (2002) 393-406
94. Shankaran S., Szego E., Eizert D., et al. Severe bronchopulmonary dysplasia. Predictors of survival and outcome. Chest 84 (1984) 607-610
95. Markestad T., and Fitzhardinge P. Growth and development in children recovering from bronchopulmonary dysplasia. J Pediatr 98 (1981) 597-602
96. Wheater M., and Rennie J. Poor prognosis after prolonged ventilation for bronchopulmonary dysplasia. Arch Dis Child Fetal Neonatal Ed 71 (1994) 210-211
97. Thomas M., Greenough A., and Morton M. Prolonged ventilation and intact survival in very low birth weight infants. Eur J Pediatr 162 (2003) 65-67
98. Yeh T., Ling Y., Lin H., et al. Outcomes at school age after postnatal dexamethasone for lung disease of prematurity. N Engl J Med 350 (2004) 1349-1351
99. Crowley P. Antenatal corticosteroid therapy: a meta-analysis of the randomized trials, 1972 to 1994. Am J Obstet Gynecol 173 (1995) 322-335
100. Crowther C., Alfirevic Z., and Haslam R. Thyrotrophin releasing hormone added to corticosteroids for women at risk of preterm birth for preventing neonatal respiratory disease. Cochrane Database Syst Rev 2 (2004) CD000019
101. Woodgate P., and Davies M. Permissive hypercapnia for the prevention of mortality and morbidity in mechanically ventilated newborn infants. Cochrane Database Syst Rev 2 (2001) CD002061
102. Greenough A., Milner A., and Dimitriou G. Synchronised mechanical ventilation for respiratory support in newborn infants. Cochrane Database Syst Rev 3 (2004) CD000456
103. Courtney S., Durand D., Asselin J., et al. High frequency oscillatory ventilation versus conventional ventilation for very low birthweight infants. N Engl J Med 347 (2002) 643-652
104. Johnson A., Peacock J., Greenough A., et al. High frequency oscillatory ventilation for the prevention of chronic lung disease. N Engl J Med 347 (2002) 633-642
105. Bollen C., Uiterwall C., and van Vught A. Cumulative metaanalysis of high-frequency versus conventional ventilation in premature neonates. Am J Resp Crit Care Med 168 (2003) 1150-1155
106. Van Marter L., Allred E., Pagano M., et al. Do clinical markers of barotrauma and oxygen toxicity explain interhospital variation in rates of chronic lung disease? The Neonatology Committee for the Developmental Network. Pediatrics 105 (2000) 1194-1201
107. Kavvadia V., Greenough A., Dimitriou G., and Hooper R. Randomised trial of fluid restriction in ventilated very low birthweight infants. Arch Dis Child 83 (2000) 91-96
108. Hartnoll G., Betremieux P., and Modi N. Randomised controlled trial postnatal sodium supplementation on oxygen dependency and body weight in 25-30 week gestational age infants. Arch Dis Child Fetal Neonatal Ed 82 (2000) 19-23
109. Singhal A., and Lucas A. Early origins of cardiovascular disease is there an underlying hypothesis?. Lancet 363 (2004) 1642-1645
110. Darlow B., and Graham P. Vitamin A supplementation for preventing morbidity and mortality in very low birthweight infants. Cochrane Database Syst Rev 4 (2002) CD000501
111. Yoder M., Chua R., and Tepper R. Effect of dexamethasone on pulmonary inflammation and pulmonary function of ventilator dependent infants with bronchopulmonary dysplasia. Am Rev Respir Dis 143 (1991) 1044-1048
112. Halliday H. Clinical trials of postnatal corticosteroids; inhaled and systemic. Biol Neonate 76 (1999) 29-40
113. Shah V., Ohlsson A., Halliday H., and Dunn M. Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birthweight neonates. Cochrane Database Syst Rev 1 (2000) CD001969
114. Jobe A. Postnatal corticosteroids for preterm infants-do what we say, not what we do. N Engl J Med 350 (2004) 1349-1351
115. Garland J., Alex C., Pauly T., et al. A three day course of dexamethasone therapy to prevent chronic lung disease in ventilated neonates: a randomised trial. Pediatrics 104 (1999) 91-99
116. Watterberg K., Gerdes J., Cole C., et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics 114 (2004) 1649-1657
117. Committee on fetus and newborn. Postnatal corticosteroids to treat or prevent chronic lung disease in premature infants. Pediatrics 109 (2002) 330-338
118. Doyle L., Halliday H., Ehrenkranz R., et al. Impact of postnatal corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease. Pediatrics 115 (2005) 655-661
119. Lister P., Iles R., Shaw B., and Cucharme F. Inhaled steroids for neonatal chronic lung disease. Cochrane Database Syst Rev 4 (1999) CD002311
120. Cole C., Colton T., Shah B., et al. Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia. N Engl J Med 340 (1999) 1005-1010
121. Dugas M., Nguyen D., Frenette L., et al. Fluticasone inhalation in moderate cases of bronchopulmonary dysplasia. Pediatrics 115 (2005) 566-572
122. Peltoniemi O., Kari A., Heinonen K., et al. Pretreatment cortisol values may predict responses to hydrocortisone administration for the prevention of BPD in high-risk infants. J Pediatr 146 (2005) 632-637
123. Davis J., Rosenfeld W., Sanders R., and Gonenne A. Prophylactic effects of recombinant human superoxide dismutase in neonatal lung injury. J Appl Physiol 74 (1993) 2234-2241
124. Davis J., Parad R., Michele T., et al. Pulmonary outcome at one year corrected age in premature infants treated at birth with recombinant CuZn superoxide dismutase. Pediatrics 111 (2003) 469-476
125. Chappell L., Seed P., Briley A., et al. Effects of antioxidants in the occurrence of pre-eclampsia in women at increased risk: a randomised trial. Lancet 354 (1999) 810-816
126. Kinsella J., Parker T., Galan H., Sheridan B., Halbower A., and Abman S. Effects of inhaled nitric oxide on pulmonary edema and lung neutrophil accumulation in severe experimental hyaline membrane disease. Pediatr Res 41 (1997) 457-463
127. Tang J., Markham N., Lin Y., et al. Inhaled nitric oxide attenuates pulmonary hypertension and improves lung growth in infant rats after neonatal treatment with a VEGF receptor inhibitor. Am J Physiol Lung Cell Mol Physiol 287 (2004) 344-351
128. Kinsella J., Walsh W., Bose C., et al. Randomised controlled trial of inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure. Lancet 354 (1999) 1061-1065
129. Banks B., Seri I., Ischiropoulos H., Merrill J., Rychik J., and Ballard R. Changes in oxygenation with inhaled nitric oxide in severe bronchopulmonary dysplasia. Pediatrics 103 (1999) 610-618
130. Schreiber M., Gin-Mestan K., Marks J., Huo D., Lee G., and Srisuparp P. Inhaled nitric oxide in premature infants with respiratory distress. N Engl J Med 349 (2003) 2099-2107
131. Van Meurs K., Wright L., Ehrenkranz R., et al. Inhaled nitric oxide for premature infants with severe respiratory failure. N Engl J Med 353 (2005) 13-22